Transmission-blocking vaccine of vivax malaria.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Parasitology international

• Publication date

  2003-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S1383-5769(02)00037-5PMID 12543142
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Transmission-blocking vaccines.

  2002cited by this paper
• Presence of three distinct ookinete surface protein genes, Pos25, Pos28-1, and Pos28-2, in Plasmodium ovale.

  2001cited by this paper
• Child mortality and malaria transmission intensity in Africa.

  2001cited by this paper
• Anti-mosquito midgut antibodies block development of Plasmodium falciparum and Plasmodium vivax in multiple species of Anopheles mosquitoes and reduce vector fecundity and survivorship

  2001cited by this paper
• The neglected burden of Plasmodium vivax malaria.

  2001cited by this paper
• Disruption of Plasmodium falciparumChitinase Markedly Impairs Parasite Invasion of Mosquito Midgut

  2001cited by this paper
• P25 and P28 proteins of the malaria ookinete surface have multiple and partially redundant functions

  2001cited by this paper
• A central role for P48/45 in malaria parasite male gamete fertility.

  2001cited by this paper
• Transmission blocking malaria vaccines.

  2001cited by this paper
• The ears of the hippopotamus: manifestations, determinants, and estimates of the malaria burden.

  2001cited by this paper
• Antibodies to Malaria Vaccine Candidates Pvs25 and Pvs28 Completely Block the Ability of Plasmodium vivax To Infect Mosquitoes

  2000cited by this paper
• Sequence diversity in rodent malaria of the Pfs28 ookinete surface antigen homologs.

  2000cited by this paper
• Micronemal Transport of Plasmodium Ookinete Chitinases to the Electron-Dense Area of the Apical Complex for Extracellular Secretion

  2000cited by this paper
• Chitinases of the Avian Malaria Parasite Plasmodium gallinaceum, a Class of Enzymes Necessary for Parasite Invasion of the Mosquito Midgut*

  2000cited by this paper
• Developmental arrest of the human malaria parasite Plasmodium falciparum within the mosquito midgut via CTRP gene disruption

  2000cited by this paper
• Malaria eradication on islands.

  2000cited by this paper
• Spatial targeting of interventions against malaria.

  2000cited by this paper
• The chitinase PfCHT1 from the human malaria parasite Plasmodium falciparum lacks proenzyme and chitin-binding domains and displays unique substrate preferences.

  1999cited by this paper
• Immunization of Mice with DNA-Based Pfs25 Elicits Potent Malaria Transmission-Blocking Antibodies

  1999cited by this paper
• The crystal structure of C-terminal merozoite surface protein 1 at 1.8 A resolution, a highly protective malaria vaccine candidate.

  1999cited by this paper
• CTRP is essential for mosquito infection by malaria ookinetes

  1999cited by this paper
• Identification of additional members define a Plasmodium falciparum gene superfamily which includes Pfs48/45 and Pfs230.

  1999cited by this paper
• Targeted Disruption of the Plasmodium berghei Ctrp Gene Reveals Its Essential Role in Malaria Infection of the Vector Mosquito

  1999cited by this paper
• Malaria : parasite biology, pathogenesis, and protection

  1998cited by this paper
• Genetic polymorphism and natural selection in the malaria parasite Plasmodium falciparum.

  1998cited by this paper
• Sequence Polymorphism in Two Novel Plasmodium vivax Ookinete Surface Proteins, Pvs25 and Pvs28, That Are Malaria Transmission-blocking Vaccine Candidates

  1998cited by this paper
• Predicted and observed alleles of Plasmodium falciparum merozoite surface protein-1 (MSP-1), a potential malaria vaccine antigen.

  1998cited by this paper
• Saccharomyces cerevisiae-Secreted Fusion Proteins Pfs25 and Pfs28 Elicit Potent Plasmodium falciparum Transmission-Blocking Antibodies in Mice

  1998cited by this paper
• Continuous in vitro propagation of the malaria parasite Plasmodium vivax.

  1997cited by this paper
• Primary structure of a novel ookinete surface protein from Plasmodium berghei.

  1997cited by this paper
• Transmission-blocking vaccines: uses and current status of development.

  1997cited by this paper
• Two antigens on zygotes and ookinetes of Plasmodium yoelii and Plasmodium berghei that are distinct targets of transmission-blocking immunity

  1997cited by this paper
• A novel malaria protein, Pfs28, and Pfs25 are genetically linked and synergistic as falciparum malaria transmission-blocking vaccines

  1997cited by this paper
• Comparison of Plasmodium yoelii ookinete surface antigens with human and avian malaria parasite homologues reveals two highly conserved regions.

  1997cited by this paper
• Minimal variation in the Pfs28 ookinete antigen from Philippine field isolates of Plasmodium falciparum.

  1997cited by this paper
• Malaria vaccine development: a multi-immune response approach

  1996cited by this paper
• Acquired transmission-blocking immunity to Plasmodium vivax in a population of southern coastal Mexico.

  1996cited by this paper
• Recombinant Pfs230, a Plasmodium falciparum gametocyte protein, induces antisera that reduce the infectivity of Plasmodium falciparum to mosquitoes.

  1995cited by this paper
• Transmission blocking immunity in Plasmodium vivax malaria: antibodies raised against a peptide block parasite development in the mosquito vector

  1995cited by this paper
• Production, Purification and Immunogenicity of a Malaria Transmission-Blocking Vaccine Candidate: TBV25H Expressed in Yeast and Purified Using Nickel-NTA Agarose

  1994cited by this paper
• Transmission‐blocking antibodies against multiple, non‐variant target epitopes of the Plasmodium falciparum gamete surface antigen Pfs230 are all complement‐fixing

  1994cited by this paper
• Saccharomyces cerevisiae recombinant Pfs25 adsorbed to alum elicits antibodies that block transmission of Plasmodium falciparum

  1994cited by this paper
• Structure and expression of a post-transcriptionally regulated malaria gene encoding a surface protein from the sexual stages of Plasmodium berghei.

  1993cited by this paper
• Cloning and expression of the gene for Plasmodium falciparum transmission-blocking target antigen, Pfs230.

  1993cited by this paper
• Transmission-blocking activity of a chitinase inhibitor and activation of malarial parasite chitinase by mosquito protease.

  1993cited by this paper
• Pgs28 belongs to a family of epidermal growth factor-like antigens that are targets of malaria transmission-blocking antibodies

  1993cited by this paper
• Cloning and expression of the gene coding for the transmission blocking target antigen Pfs48/45 of Plasmodium falciparum.

  1993cited by this paper
• Minimal efficacy requirements for malarial vaccines to significantly lower transmission in epidemic or seasonal malaria.

  1993cited by this paper
• Single amino acid variation in the ookinete vaccine antigen from field isolates of Plasmodium falciparum.

  1992cited by this paper
• Transmission blocking immunity to human Plasmodium vivax malaria in an endemic population in Kataragama, Sri Lanka

  1992cited by this paper
• Properties of epitopes of Pfs 48/45, a target of transmission blocking monoclonal antibodies, on gametes of different isolates of Plasmodium falciparum

  1990cited by this paper
• Target antigens of transmission blocking immunity of Plasmodium vivax malaria. Characterization and polymorphism in natural parasite isolates.

  1990cited by this paper
• Restricted or absent immune responses in human populations to Plasmodium falciparum gamete antigens that are targets of malaria transmission-blocking antibodies

  1989cited by this paper
• Comparison of the primary structure of the 25 kDa ookinete surface antigens of Plasmodium falciparum and Plasmodium gallinaceum reveal six conserved regions.

  1989cited by this paper
• Minimal variation in a vaccine candidate from the sexual stage of Plasmodium falciparum.

  1989cited by this paper
• Differential non-responsiveness in humans of candidate Plasmodium falciparum vaccine antigens.

  1989cited by this paper
• Monoclonal and polyclonal antibodies both block and enhance transmission of human Plasmodium vivax malaria.

  1988cited by this paper
• A vaccine candidate from the sexual stage of human malaria that contains EGF-like domains

  1988cited by this paper
• Immunity to sexual stages of malaria parasites.

  1988cited by this paper
• The 230-kDa gamete surface protein of Plasmodium falciparum is also a target for transmission-blocking antibodies.

  1987cited by this paper
• Biosynthesis of two stage-specific membrane proteins during transformation of Plasmodium gallinaceum zygotes into ookinetes.

  1985cited by this paper
• Sequential expression of antigens on sexual stages of Plasmodium falciparum accessible to transmission-blocking antibodies in the mosquito

  1985cited by this paper
• A surface protein expressed during the transformation of zygotes of Plasmodium gallinaceum is a target of transmission-blocking antibodies

  1984cited by this paper
• Target antigens of transmission-blocking immunity on gametes of plasmodium falciparum

  1983cited by this paper
• Immunisation against gametes and asexual erythrocytic stages of a rodent malaria parasite

  1979cited by this paper
• Malaria immunization in Rhesus monkeys. A vaccine effective against both the sexual and asexual stages of Plasmodium knowlesi

  1978cited by this paper
• Successful immunization against the sexual stages of Plasmodium gallinaceum.

  1976cited by this paper
• Malaria transmission blocked by immunisation with gametes of the malaria parasite

  1976cited by this paper

• Genetic polymorphisms of Plasmodium vivax transmission-blocking vaccine candidates Pvs48/45 and Pvs47 in Thailand

  2025cites this paper
• Genetic polymorphisms of Plasmodium vivax ookinete (sexual stage) surface proteins (Pvs25 and Pvs28) from Thailand.

  2024cites this paper
• Transdermal Transmission Blocking Vaccine for Malaria Using a Solid-in-Oil Dispersion.

  2022cites this paper
• Highly efficient protein expression of Plasmodium vivax surface antigen, Pvs25, by silkworm and its biochemical analysis.

  2022cites this paper
• Highly efficient protein expression of Plasmodium vivax surface antigen, Pvs25 by silkworm, Bombyx mori, and its biochemical analysis

  2022cites this paper
• Genetic diversity of transmission-blocking vaccine candidate antigens Pvs25 and Pvs28 in Plasmodium vivax isolates from China

  2022cites this paper
• Plasmodium vivax transmission-blocking vaccines: Progress, challenges and innovation.

  2021cites this paper
• Parasite-Host Interaction and Pathophysiology Studies of the Human Relapsing Malarias Plasmodium vivax and Plasmodium ovale Infections in Non-Human Primates

  2021cites this paper
• Evaluation of two sexual-stage antigens as bivalent transmission-blocking vaccines in rodent malaria

  2021cites this paper
• Identification of Novel Malaria Transmission-Blocking Vaccine Candidates

  2021cites this paper
• Genetic diversity and natural selection of transmission-blocking vaccine candidate antigens Pvs25 and Pvs28 in Plasmodium vivax Myanmar isolates.

  2019cites this paper
• Immune Responses to the Sexual Stages of Plasmodium falciparum Parasites

  2019cites this paper
• Characterization of Plasmodium berghei Pbg37 as Both a Pre- and Postfertilization Antigen with Transmission-Blocking Potential

  2018cites this paper
• Asymptomatic Plasmodium vivax parasitaemia in the low-transmission setting: the role for a population-based transmission-blocking vaccine for malaria elimination

  2018cites this paper
• Identification of three ookinete-specific genes and evaluation of their transmission-blocking potentials in Plasmodium berghei.

  2016cites this paper
• Malaria Vaccines in Clinical Development: Introduction and Recombinant/Subunit Approaches

  2016cites this paper
• Multivalent Shigella Enterotoxigenic Escherichia coli Vaccine

  2016cites this paper
• Role of plasmodium translationally repressed gene products in malaria transmission

  2015cites this paper
• Rapid genotyping of Plasmodium vivax Pvs25 and Pv38 genes by using mismatch specific endonuclease.

  2014cites this paper
• 600-606 Lim CS.pmd

  2014cites this paper
• Tricomponent Complex Loaded with a Mosquito-Stage Antigen of the Malaria Parasite Induces Potent Transmission-Blocking Immunity

  2014cites this paper
• Immune Responses to Defined Plasmodium falciparum Antigens and Disease Susceptibility in Two Subpopulations of Northern India

  2013influential citation
• Malaria Vaccine Development: A Challenge for Africa

  2013cites this paper
• Limited sequence polymorphisms of four transmission-blocking vaccine candidate antigens in Plasmodium vivax Korean isolates

  2013cites this paper
• Molecular Characterization of the Carboxypeptidase B1 of Anopheles stephensi and Its Evaluation as a Target for Transmission-Blocking Vaccines

  2013cites this paper
• Natural acquisition of immunity to Plasmodium vivax: epidemiological observations and potential targets.

  2013cites this paper
• Edible vaccine: a new platform for the development of malaria vaccine.

  2012cites this paper
• Platform for Plasmodium vivax vaccine discovery and development.

  2011cites this paper
• Epidemiology and Infectivity of Plasmodium falciparum and Plasmodium vivax Gametocytes in Relation to Malaria Control and Elimination

  2011cites this paper
• Avaliação das propriedades imunogênicas das proteínas 3α e 3β da superfície do merozoíto de Plasmodium vivax

  2011cites this paper
• Malaria transmission blocking immunity and sexual stage vaccines for interrupting malaria transmission in Latin America.

  2011influential citation
• Adenovirus-vectored Plasmodium vivax ookinete surface protein, Pvs25, as a potential transmission-blocking vaccine.

  2011cites this paper
• Genetic diversity of transmission-blocking vaccine candidates Pvs25 and Pvs28 in Plasmodium vivax isolates from Yunnan Province, China

  2011cites this paper
• Worldwide sequence conservation of transmission-blocking vaccine candidate Pvs230 in Plasmodium vivax.

  2011cites this paper
• Molecular studies on plasmodium during development in the mosquito

  2011cites this paper
• Current status of Plasmodium vivax vaccine

  2010cites this paper
• The wheat germ cell-free protein synthesis system: a key tool for novel malaria vaccine candidate discovery.

  2010cites this paper
• Plasmodium vivax Ookinete Surface Protein Pvs25 Linked to Cholera Toxin B Subunit Induces Potent Transmission-Blocking Immunity by Intranasal as Well as Subcutaneous Immunization

  2010cites this paper
• Malaria vaccine candidate diversity offers challenges and opportunities for effective vaccine development.

  2009influential citation
• Genetic diversity of transmission blocking vaccine candidate (Pvs25 and Pvs28) antigen in Plasmodium vivax clinical isolates from Iran.

  2009cites this paper
• Analysis of von Willebrand factor A domain-related protein (WARP) polymorphism in temperate and tropical Plasmodium vivax field isolates

  2009cites this paper
• Flipping the paradigm on malaria transmission-blocking vaccines.

  2008cites this paper
• Efeito da refeição sanguínea, anticorpos e infecções mistas no desenvolvimento esporogónico de Plasmodium spp.

  2008cites this paper
• Malaria transmission-blocking vaccines: the bonus of effective malaria control.

  2007cites this paper
• A case for whole-parasite malaria vaccines.

  2007cites this paper
• Plasmodium yoelii: the effect of second blood meal and anti-sporozoite antibodies on development and gene expression in the mosquito vector, Anopheles stephensi.

  2007cites this paper
• Plasmodium vivax: impaired escape of Vk210 phenotype ookinetes from the midgut blood bolus of Anopheles pseudopunctipennis.

  2007cites this paper
• An update on the search for a Plasmodium vivax vaccine.

  2007cites this paper
• Laboratory assays for the detection of malaria transmission reducing activity

  2007influential citation
• Plasmodium P25 and P28 Surface Proteins: Potential Transmission-Blocking Vaccines

  2007cites this paper
• Mosquito stage, transmission blocking vaccines for malaria

  2007cites this paper
• Carboxypeptidases B of Anopheles gambiae as Targets for a Plasmodium falciparum Transmission-Blocking Vaccine

  2007cites this paper
• Production of nitric oxide by murine macrophages induced by lipophosphoglycan of Leishmania major.

  2006cites this paper
• Malaria: therapy, genes and vaccines.

  2006cites this paper
• High road, low road? Choices and challenges on the pathway to a malaria vaccine

  2006cites this paper
• The ecology and evolution of malaria : laboratory studies of Plasmodium chabaudi and its rodent and insect hosts.

  2006cites this paper
• Population dynamics of sporogony for Plasmodium vivax parasites from western Thailand developing within three species of colonized Anopheles mosquitoes

  2006cites this paper
• Evaluation of the standard membrane feeding assay (SMFA) for the determination of malaria transmission-reducing activity using empirical data

  2005cites this paper
• Induction of transmission-blocking immunity in Aotus monkeys by vaccination with a Plasmodium vivax clinical grade PVS25 recombinant protein.

  2005cites this paper
• Plasmodium vivax: transmission-blocking immunity in a malaria-endemic area of Colombia.

  2005cites this paper
• Do malaria ookinete surface proteins P25 and P28 mediate parasite entry into mosquito midgut epithelial cells?

  2005cites this paper
• [Malaria transmission-blocking vaccine development].

  2005cites this paper
• Identification, expression, localization and serological characterization of a tryptophan-rich antigen from the human malaria parasite Plasmodium vivax.

  2005cites this paper
• New Challenge to Parasite Immunology

  2005cites this paper
• Why do we need to know more about mixed Plasmodium species infections in humans?

  2004cites this paper
• Malaria vaccine: are we anywhere close?

  2004cites this paper
• Evaluation of the standard membrane feeding assay (SMFA) for the determination of malaria transmission-reducing activity using empirical data

  2004cites this paper
• Crystallization and preliminary X-ray analysis of the Plasmodium vivax sexual stage 25 kDa protein Pvs25, a transmission-blocking vaccine candidate for malaria.

  2004cites this paper
• Plasmodium vivax transmission: chances for control?

  2004cites this paper
• A rapid genotyping method for the vivax malaria transmission-blocking vaccine candidates, Pvs25 and Pvs28.

  2004cites this paper
• Microbe-vector interactions in vector-borne diseases.

  2004cites this paper
• Engineering Plasmodium-refractory phenotypes in mosquitoes.

  2003cites this paper
• The dynamics of interactions between Plasmodium and the mosquito: a study of the infectivity of Plasmodium berghei and Plasmodium gallinaceum, and their transmission by Anopheles stephensi, Anopheles gambiae and Aedes aegypti.

  2003cites this paper
• Blocking of transmission to mosquitoes by antibody to Plasmodium vivax malaria vaccine candidates Pvs25 and Pvs28 despite antigenic polymorphism in field isolates.

  2003cites this paper
• Serum antibodies induced by intranasal immunization of mice with Plasmodium vivax Pvs25 co-administered with cholera toxin completely block parasite transmission to mosquitoes.

  2003cites this paper
• Chapter 21. New therapies for malaria

  2003cites this paper
• Medicinal Plants of Ethiopia: Conservation, Traditional Knowledge, and Sustainable Use.

  year unknowncites this paper